Drug Type Small molecule drug |
Synonyms EGF-Au NP-Pc 4, PC-4 |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC39H35N9O2Si2 |
InChIKeyMXKIUUUHVLFVJF-UHFFFAOYSA-N |
CAS Registry135719-28-7 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Actinic Keratosis | Phase 1 | United States | 01 Sep 2004 | |
| Bowen's Disease | Phase 1 | United States | 01 Sep 2004 | |
| Breast Cancer | Phase 1 | United States | 01 Aug 2001 | |
| Head and Neck Neoplasms | Phase 1 | United States | 01 Aug 2001 | |
| Lymphoma | Phase 1 | United States | 01 Aug 2001 | |
| Neoplasm Metastasis | Phase 1 | United States | 01 Aug 2001 | |
| Sarcoma | Phase 1 | United States | 01 Aug 2001 | |
| Skin Neoplasms | Phase 1 | United States | 01 Aug 2001 | |
| Glioma | Preclinical | United States | 15 Apr 2011 |
Phase 1 | 11 | pharmacological study+silicon phthalocyanine 4 | tilawwyqey = rgaqxjxtyt qfueeoucdx (iclgvvgyjl, ikydnzlntl - dtnbvmnryz) View more | - | 16 May 2019 |





